G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 94 filers reported holding G1 THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $696,000 | -42.8% | 51,899 | -6.3% | 0.01% | -36.4% |
Q2 2021 | $1,216,000 | +117.1% | 55,417 | +14.3% | 0.01% | +37.5% |
Q3 2020 | $560,000 | -55.2% | 48,478 | -5.8% | 0.01% | -52.9% |
Q2 2020 | $1,249,000 | +65.9% | 51,480 | -24.7% | 0.02% | +41.7% |
Q1 2020 | $753,000 | -62.4% | 68,324 | -9.7% | 0.01% | -25.0% |
Q4 2019 | $2,001,000 | +17.4% | 75,692 | +1.1% | 0.02% | +23.1% |
Q3 2019 | $1,705,000 | -29.1% | 74,852 | -4.5% | 0.01% | -27.8% |
Q2 2019 | $2,404,000 | +61.2% | 78,412 | -12.7% | 0.02% | +63.6% |
Q1 2019 | $1,491,000 | -9.4% | 89,816 | +4.5% | 0.01% | -15.4% |
Q4 2018 | $1,646,000 | -46.7% | 85,931 | +45.4% | 0.01% | -35.0% |
Q3 2018 | $3,091,000 | +49.8% | 59,114 | +24.6% | 0.02% | +53.8% |
Q2 2018 | $2,063,000 | +46.0% | 47,458 | +24.4% | 0.01% | +18.2% |
Q1 2018 | $1,413,000 | +126.8% | 38,151 | +21.5% | 0.01% | +175.0% |
Q4 2017 | $623,000 | -9.8% | 31,409 | +13.1% | 0.00% | -20.0% |
Q3 2017 | $691,000 | +55.6% | 27,766 | +9.1% | 0.01% | +66.7% |
Q2 2017 | $444,000 | – | 25,449 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |